![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Alzheimer’s disease is a neurodegenerative disorder characterized by cognitive and behavioral deficits. Donepezil and memantine are two medications used to treat the symptoms of cognitive decline in Alzheimer’s disease. A modeled cost–effectiveness analysis found that treatment with donepezil to be less costly and more effective than no treatment or treatment with memantine in Germany. However, the model drew on non-German population data and could have been more transparent with regard to ‘back-end’ processes. In addition, the authors would question the extent to which the differences in effectiveness between treatments would be considered clinically significant. Identifying sources of cost savings for donepezil remains an important issue for future consideration.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.